Patents - Global Data - Dimensions
Grant
Leucine-rich repeat kinase 2 (LRRK2) inhibitors
Applicants
- Lundbeck (Denmark)
[NORA names: Lundbeck; Private Research; Denmark; Europe, EU; Nordic; OECD]
Abstract
The present invention is directed to compounds of formula IIa
These compounds are considered useful for the treatment of diseases associated with leucine-rich repeat kinase 2 (LRRK2) such as Parkinson's disease. Furthermore, the invention relates to pharmaceutical compositions comprising said compounds.
Patent Family Records (2)
MACROCYCLIC LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS
H LUNDBECK AS, Ligand Pharmaceuticals (United Kingdom), Lundbeck (Denmark), VERNALIS R&D LTD JENSEN THOMAS, ANDERSEN THOMAS, JESSING MIKKEL, (...more)
2024, WO-2024056775-A1
Leucine-rich repeat kinase 2 (LRRK2) inhibitors
H Lundbeck AS, Lundbeck (Denmark) JENSEN THOMAS, ANDERSEN THOMAS, JESSING MIKKEL, (...more)
2024, US-11958865-B1